In the U.S., there are currently thirteen approved anti-cancer therapies with recognized antiangiogenic properties in oncology. These agents, which interrupt critical cell signaling pathways involved in tumor angiogenesis and growth, comprise of three primary categories:
1) monoclonal antibodies directed against specific proangiogenic growth factors and/or their receptors; and
2) small molecule tyrosine kinase inhibitors (TKIs) of multiple proangiogenic growth factor receptors;
3) inhibitors of mTOR (mammalian target of rapamycin).
In addition, at least two other approved angiogenic agents may indirectly inhibit angiogenesis through mechanisms that are not completely understood. Finally, in the field of dermatology, there are several agents used for neoplasms of the skin.
For a list of anti-angiogenic agents please check our Treatments page.